The 4th U-PGx Personalized Medicine Day will be organized in Stockholm, Sweden. The meeting will be co-organized from the Golden Helix Foundation and the Karolinska Institutet, both partners of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353).
The meeting will be held in the STRIX lecture hall (address: von Eulers väg 4, Karolinska Institutet 171 65 Solna).
This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.
| Co-organized by: |
Funded by:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668353.
IntroductionAbout U-PGXSpeakersScientific ProgramRegistrationGalleryThe 4th U-PGx Personalized Medicine Day will be organized in Stockholm, Sweden. The meeting will be co-organized from the Golden Helix Foundation and the Karolinska Institutet, both partners of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353).
The meeting will be held in the STRIX lecture hall (address: von Eulers väg 4, Karolinska Institutet 171 65 Solna).
This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.
| Co-organized by: |
Funded by:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668353.
Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in pharmacogenomics and several commercially available pharmacogenomics tests, its application in routine patient care remains very limited. The U-PGx consortium will address major challenges and obstacles for implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important pharmacogenomics markers is cost-effective and results in a better outcome for patients. With the pre-emptive pharmacogenomics testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive pharmacogenomics testing will be conducted at a large scale in seven existing European health care environments in the Netherlands, Spain, UK, Italy, Austria, Greece, and Slovenia.
Invited speakers
Organizing Committee
Magnus Ingelman-Sundberg; Professor, Karolinska Institutet, Stockholm, Sweden
George P. Patrinos; Associate Professor, University of Patras Department of Pharmacy, Patras, Greece
Keynote Speaker
Matthias Schwab (Stuttgart, DE)
Plenary Speakers and Session Chairs
Ingolf Cascorbi (Kiel, DE)
Erik Eliasson (Stockholm, SE)
Henk-Jan Guchelaar (Leiden, NL)
Magnus Ingelman-Sundberg (Stockholm, SE)
Siv Jönsson (Uppsala, SE)
Marin Jukic (Stockholm SE)
George P. Patrinos (Patras, GR)
Richard Rosenquist Brandell (Stockholm, SE)
Julia Stingl (Bonn, DE)
Scientific Program
8:30 – 9:30 Registration
09:30 – 09:45 Welcome address
Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden.
SESSION I
Co-chairs: Siv Jönsson (Uppsala, SE), Magnus Ingelman-Sundberg (Stockholm, SE)
09:45 – 10:15 Making pharmacogenomics available to every patient everywhere: The Ubiquitous Pharmacogenomics Project
Henk-Jan Guchelaar; Leiden University Medical Center, Leiden, the Netherlands
10:15 – 10:45 Implementation of pharmacogenomics at Karolinska Institutet
Erik Eliasson, Karolinska Institutet, Stockholm, Sweden
10:45 – 11:30 Keynote lecture
Precision Medicine and Pharmacogenomics: Update and future directions
Matthias Schwab, Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
11:30 – 12.00 Regulatory aspects of Pharmacogenomics
Julia Stingl, Federal Institute for Drugs & Medical Devices, Bonn, Germany
12:00 – 13:00 Lunch Break
SESSION II
Co-chairs: George P. Patrinos (Patras, GR), Magnus Ingelman-Sundberg (Stockholm, SE)
13:00 – 13:30 Rare mutations and NGS-based pharmacogenomic advice
Magnus Ingelman-Sundberg; Karolinska Institutet, Stockholm, Sweden
13:30 – 14:00 Translational pharmacogenomics: An information technology perspective
George P. Patrinos; University of Patras, Department of Pharmacy, Patras, Greece
14:00 – 14:30 Pharmacogenomics in oncology
Ingolf Cascorbi, Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, DE University of Kiel, Germany
14:30 – 14:50 Coffee/Tea break
14:50 – 15:20 Pharmacogenomics in central nervous system diseases
Marin Jukic, Karolinska Institutet, Stockholm, Sweden
15:20 – 15:40 Genomic Medicine Sweden: Implementation of pharmacogenomics into clinical practice in Sweden
Richard Rosenquist Brandell, Karolinska Institutet, Stockholm, Sweden
15:40 – 16:30 Round table discussion “Introducing personalized medicine into clinical practice: Realities and expectations”
Participants: Magnus Ingelman-Sundberg (moderator), George P. Patrinos, Henk-Jan Guchelaar, Julia Stingl, Matthias Schwab, Ingolf Cascorbi, Erik Eliasson
16:30 Closing remarks
Registration
Registration for this event is closed.
